Helix BioPharma Corp.

Helix BioPharma Corp.

February 28, 2005 15:18 ET

Helix Signs Agreement With Apotex




FEBRUARY 28, 2005 - 15:18 ET

Helix Signs Agreement With Apotex

AURORA, ONTARIO--(CCNMatthews - Feb. 28, 2005) - Helix BioPharma is
pleased to announce that its wholly-owned subsidiary, PharmaDerm
Laboratories, has entered into an agreement with Apotex, the largest
Canadian-owned pharmaceutical company, to identify and characterize a
lead formulation for Apotex's burgeoning topical therapeutic product

PharmaDerm Laboratories specializes in the development of novel,
semi-solid drug products, based on its proprietary technologies.
PharmaDerm Laboratories is the birthplace of Helix's lead product in
development, Topical Interferon Alpha-2b, which is currently in clinical
trials in Germany.

"We are very pleased that Apotex has recognized our topical drug
development expertise, and we hope this agreement will be the first in a
series of opportunities to collaborate together," said Mr. John
Docherty, President of PharmaDerm Laboratories.

About Apotex

The Apotex Group of Companies develops, manufactures, and markets over
250 pharmaceutical products for the Canadian and international markets.
Apotex currently distributes its products in more than 115 countries
around the world.

About Helix BioPharma

Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives
include its Topical Interferon Alpha-2b, for the treatment of conditions
caused by the human papilloma virus, and its novel DOS47 new drug
candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of
this News Release. This News Release contains certain forward-looking
statements regarding the Company's future collaboration with Apotex.
Forward-looking statements can be identified by the use of
forward-looking terminology such as "to", "hopes", or variations thereon
or comparable terminology referring to future events or results. Forward
looking statements are statements about the future and are inherently
uncertain, and the Company's actual results could differ materially from
those anticipated in these forward-looking statements as a result of
numerous factors, including without limitation, research & development
risks, uncertainty whether PharmaDerm will be successful in identifying
and characterizing a lead formulation for Apotex, uncertainty whether
PharmaDerm will enter into any future collaborations with Apotex,
Helix's need for additional future capital, which may not be available
in a timely manner or at all, as well as a description of other risks
and uncertainties affecting Helix and its business, as contained in news
releases and filings with the Canadian Securities Regulatory
Authorities, any of which could cause actual results to vary materially
from current results or Helix's anticipated future results. The Company
assumes no obligation to update the information contained in this News

WKN: 918 846


Contact Information